Dr. Daniel A. Duprez, MD

Dr. Duprez practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Duprez's NPI, 1609807825, was assigned on July 5, 2006. Dr. Duprez holds Minnesota license 46542.

Dr. Duprez's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Duprez's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Duprez is also affiliated with M Health Fairview St. John's Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Duprez to 3 more group practices and clinics, 2 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Duprez practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Duprez's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Duprez is licensed in Minnesota.

CMS data shows 157 Medicare services from Dr. Duprez across 5 procedure codes in 2024, for 154 Medicare patients. Medicare paid $11,090 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 154 Medicare patients who saw Dr. Duprez in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Duprez's median patient age at 67, with 43% women.

In 2024, Dr. Duprez wrote 2,218 Medicare Part D claims for 308 patients. 81% of them were for generic drugs. CMS names the drug for 2,110 of them, across 33 drugs with 11 or more claims each, at $490,441 in total drug cost. In 2023, CMS named 2,055 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Duprez for performance year 2024, reported as part of a group. Dr. Duprez accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Duprez as offering telehealth.

Dmand AI links 170 papers to Dr. Duprez, published from 2007 to 2025. 2018 was the busiest year, with 12. The most frequent topics are Cardiovascular Diseases, Atherosclerosis and Blood Pressure. Dr. Duprez has published most often in J Am Heart Assoc. Dr. Duprez's most frequent co-authors are David Alan Bluemke, MD, Julio Alonso Chirinos, MD and Joachim Hanno Ix, MD.

Dmand AI links Dr. Duprez to 3 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Hypertriglyceridemia, Myocardial Infarction and Hyperlipidemias. Arrowhead Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 34 general payments to Dr. Duprez from 8 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 67% of the total. Sanofi and Genzyme US Companies paid the most, $10,799. It also lists 1 research payment totaling $85 in 2017.